-
November 8, 2021 Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration...
-
November 5, 2021 Psychedelic Business Spotlight: November 5This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher...
-
November 4, 2021 Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with PsilocybinCompass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial,...
-
November 4, 2021 FDA Approves First Clinical Trial Using Naturally Sourced PsychedelicsThis trial, using Filament Health's botanical drug candidates, is the first to assess the direct...
-
November 4, 2021 Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!! The trial...
-
November 2, 2021 TRIPP Wants You to ‘Be Here Now,’ With or Without Ram DassPsychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher's...
-
November 1, 2021 Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser"Something that people used to speak about only in whispers is now standard policy," says...
-
October 30, 2021 NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMTNEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS,...
-
October 29, 2021 Psychedelic Business Spotlight: October 29This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder;...
-
October 22, 2021 Psychedelic Business Spotlight: October 22This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field...
